[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
January 14, 1974

Against Generics

Author Affiliations

Santa Ana, Calif

JAMA. 1974;227(2):204. doi:10.1001/jama.1974.03230150052027

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


To the Editor.—  I have read with considerable interest and sadness the exchange of letters by D. W. Duhme, MD, and D. O. Schiffman, PhD (226:200, 1973), regarding Antisubstitution Laws. Apparently Dr. Duhme believes that "shopping to find the lowest price" is the prime factor in selecting a brand of drugs along with "assurance of adequate quality (usually supplied by the FDA)." Dr. Duhme further stated that "no physician's clinical experience is adequate to make valid distinctions between different brands of the same drug," that the physician's training doesn't prepare him for this task, and that they prescribe brand names because they don't know the generic names. He thinks that the Pharmaceutical Manufacturers Association supports antisubstitution laws "out of obvious financial self-interest" and he can't understand the position of the American Medical Association in supporting such antisubstitution legislation.I should like to add my support to the arguments presented by